| Title: |
Relugolix in treatment of prostate cancer: a review. |
| Authors: |
Kyriazis, Ioannis; Bellos, Themistoklis; Katsimperis, Stamatios; Angelopoulos, Panagiotis; Neofytoy, Panagiotis; Varkarakis, Ioannis; Skolarikos, Andreas; Papatsoris, Athanasios |
| Source: |
Archives of Italian Urology & Andrology / Archivio Italiano di Urologia Andrologia; 2025, Vol. 97 Issue 4, pN.PAG-N.PAG, 1p |
| Subject Terms: |
Prostate cancer; Androgen deprivation therapy; Hormone therapy; Luteinizing hormone releasing hormone receptors; Treatment effectiveness; Cost effectiveness; Gonadotropin releasing hormone; Cardiovascular diseases risk factors |
| Abstract: |
Background: Androgen deprivation therapy (ADT) is a cornerstone treatment for advanced prostate cancer. While effective, traditional injectable luteinizing hormone-releasing hormone (LHRH) agonists are associated with an initial testosterone flare and potential cardiovascular risks. Relugolix is a novel, oral gonadotropin-releasing hormone (GnRH) antagonist developed to provide rapid suppression without a testosterone flare. This review synthesizes the latest evidence on the efficacy, safety, and clinical utility of relugolix. Methods: This non-systematic review was conducted via a search of PubMed and MEDLINE databases up to July 2025 using the terms "relugolix" AND "ADT" OR "Androgen Deprivation Therapy" AND "Prostate Cancer." Only original studies in English were included. Results: The phase III HERO trial established the superiority of relugolix over leuprolide, demonstrating higher rates of sustained castration (96.7% vs 88.8%) and a significantly faster onset of action. Relugolix also showed a 54% reduction in major cardiovascular adverse events. Furthermore, it exhibited equivalent efficacy to injectable degarelix when combined with radiotherapy, but with more robust testosterone recovery after treatment cessation (52% vs 16%). Real-world data indicates high patient adherence to the oral regimen, and a cost-effectiveness analysis suggests it is a cost-effective option despite a higher drug cost. Conclusions: Relugolix represents a significant advancement in ADT, offering a potent, oral alternative with a rapid onset of action, a superior cardiovascular safety profile, and improved testosterone recovery. It provides clinicians with a valuable option for treating advanced prostate cancer, particularly in patients with cardiovascular comorbidities. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Archives of Italian Urology & Andrology / Archivio Italiano di Urologia Andrologia is the property of PAGEPress and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |